Kangstem Biotech Competitors and Similar CompaniesClear all

Kangstem Biotech's competitors and similar companies include Sanofi, Phyton Biotech, Ventus Therapeutics and DeNovaMed.

	Kangstem Biotech Kangstem Biotech (강스템바이오텍) is a biopharmaceutical company that focuses on blood-derived stem cell therapy.	Sanofi Sanofi is a healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.	Phyton Biotech Phyton Biotech is a company that specializes in the pharmaceutical plant cell fermentation (PCF) technology.	Ventus Therapeutics Ventus Therapeutics is a company that develops small molecule therapeutics intended to target key innate immune pathways.	DeNovaMed DeNovaMed is a pharmaceutical company specializing in therapeutic approaches to combat bacterial infections.
Founding Date	Founding Date 2010	Founding Date 1994	Founding Date 2009	Founding Date N/A	Founding Date 2006
Type	Type Public	Type Public	Type Private	Type Private	Type Private
Tags	Tags Healthcare biotech drug development life sciences pharma therapy	Tags Healthcare biotech drug development life sciences pharma therapy	Tags Healthcare biotech drug development life sciences pharma therapy	Tags Healthcare biotech drug development life sciences pharma therapy	Tags Healthcare biotech drug development life sciences pharma therapy
Locations	Locations KR HQ	Locations Paris, FR HQ Hydra, DZ Buenos Aires, AR Macquarie Park, AU Melbourne, AU Virginia, AU Wien, AT see more	Locations Delta, CA HQ Ahrensburg, DE	Locations Montréal, CA HQ Waltham, US	Locations Halifax, CA HQ Toronto, CA
Employees	Employees 97	Employees 82,878	Employees 1232% increase	Employees 952% increase	Employees 6
Financial
Revenue (est.)	Revenue (est.) ₩7.7b (FY, 2024)	Revenue (est.) €45.4b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods ₩838.6m (FY, 2024)	Cost of goods €11.6b (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit ₩7.1b (FY, 2024)	Gross profit €37.6b (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit N/A
Net income	Net income (₩7.1b) (FY, 2024)	Net income €8b (FY, 2025)	Net income N/A	Net income N/A	Net income N/A
Funding
Latest funding round	Latest funding round N/A	Latest funding round N/A	Latest funding round N/A	Latest funding round $ 100m (about 5 years ago)	Latest funding round $ 500k (about 14 years ago)
Total funding raised	Total funding raised N/A	Total funding raised $ 310m	Total funding raised N/A	Total funding raised $ 160m	Total funding raised N/A